SCHEMBL5658730

SCHEMBL5658730

O=C(Nc1cccc(C2CCNCC2)c1)C1CC1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
USP2 O75604 1/20 0.54
LMNA P02545 1/20 0.54
HPGD P15428 1/20 0.54
HTT P42858 1/20 0.54
F10 P00742 3/20 0.50
NPSR1 Q6W5P4 1/20 0.50
BRAF P15056 1/20 0.49
HTR2C P28335 2/20 0.49
ULK1 O75385 1/20 0.48
ALDH1A1 P00352 1/20 0.48
MEN1 O00255 1/20 0.48
MAPT P10636 1/20 0.48
GFER P55789 1/20 0.48
KMT2A Q03164 1/20 0.48
SIRT2 Q8IXJ6 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4098389 0.84 HTR2C (0.54) BRAFHTR2CALDH1A1
SCHEMBL3556953 0.83 POLB (0.52) GAALMNABRAFHTR2CMEN1
Hydrochloric Acid SCHEMBL3337152 0.83 HTR2C (0.55) BRAFHTR2CALDH1A1
SCHEMBL5324244 0.82 HTR2C (0.55) HTR2CALDH1A1
SCHEMBL1720856 0.81 MGLL (0.56) GAASMN1; SMN2USP2LMNAHPGD
SCHEMBL4791557 0.81 DRD2 (0.54) BRAFHTR2C
SCHEMBL4141969 0.80 HPGD (0.69) GAASMN1; SMN2LMNAHPGDF10
SCHEMBL6223115 0.80 NPC1 (0.54) GAASMN1; SMN2USP2LMNAHPGD
SCHEMBL28431130 0.79 GRK2 (0.58) GAASMN1; SMN2USP2LMNAHPGD
SCHEMBL27347877 0.79 F10 (0.63) SMN1; SMN2USP2HTTF10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043080-A1 Substituted anilinic piperidines as MCH selective antagonists MARZABADI MOHAMMAD R 2007-02-22 US disclosed
US-7067534-B1 Substituted anilinic piperidines as MCH selective antagonists H. LUNDBECK A/S (DK) 2006-06-27 US disclosed
CN-1735595-A Substituted alkyl amido piperidines LUNDBECK & CO AS H (DK) 2006-02-15 CN disclosed
CN-1671386-A Substituted anilinic piperidines as MCH selective antagonists LUNDBECK & CO AS H (DK) 2005-09-21 CN disclosed
EP-1411942-A4 SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS SYNAPTIC PHARMA CORP (US) 2005-01-26 EP disclosed
EP-1411942-A1 SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS Synaptic Pharmaceutical Corporation (US) 2004-04-28 EP disclosed
US-6727264-B1 MELANIN CONCENTRATING HORMONE-1 RECEPTOR ANTAGONISTS; SLEEP, EATING, SEXUAL DISORDERS SYNAPTIC PHARMACEUTICAL CORPORATION 2004-04-27 US disclosed
WO-2003004027-A1 SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043080-A1 Substituted anilinic piperidines as MCH selective antagonists MCHR1, MCHR2, MC1R GAA 1169/4885SMN1; SMN2 1266/4885USP2 1934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.